Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

Clinical Pharmacokinetics

Volumn 36, Issue SUPPL. 1, 1999, Pages 21-31

  Cass, Lindsey M R ^a   Brown, Joanne ^b   Pickford, Matthew ^b   Fayinka, Susan ^a   Newman, Stephen P ^b   Johansson, Carl J ^a   Bye, Alan ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; TECHNETIUM 99M; ZANAMIVIR;

ADULT; ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; COUGHING; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FAINTNESS; FEMALE; HEADACHE; HERPES; HUMAN; HUMAN EXPERIMENT; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG EVALUATION; FEMALE; GUANIDINES; HUMANS; LUNG; MALE; PYRANS; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SAFETY; SIALIC ACIDS; TECHNETIUM; ZANAMIVIR;

EID: 0032999877     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936001-00003     Document Type: Article

References (20)

1. 1. Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol 1979; 24: 176-80
2. 2. Newman SP, Clark AR, Talaee N, et al. Pressurised aerosol deposition in the human lung with and without an 'open' spacer. Thorax 1989; 44: 706-10
3. 3. Nicholson KG. Human influenza. In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influenza. Ch. 19. Oxford: Blackwell Science, 1998
4. 4. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst 1993; 10: 65-109
5. 5. Borgström L, Asking L, Beckman O, et al. Dose variation, within and between individuals, with different inhalation systems. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press, 1996: 19-24
6. 6. Newman SP. Variability in drug delivery from aerosol inhalers in vitro and in vivo. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press, 1996: 11-8
7. 7. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994; 102: 127-32
8. 8. Newman SP. Characteristics of radiolabelled and unlabelled inhaler formulations. J Aerosol Med 1996; 9 Suppl. 1: S37-S47
9. 9. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 1998; 11 Suppl. 1: S97-104
10. 10. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9
11. 11. Widdicombe JG. Airway surface liquid. In: Rogers DF, Lethem MI, editors. Concepts and measurements in airway mucus: basic mechanisms and clinical perspectives. Basel: Birkhauser Verlag, 1997: 1-17
12. 12. Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford Textbook of Medicine. Vol 2: 3rd ed. Sections 11-17 and index. Table II. Oxford: Oxford Medical Publications, 1996: 2602
13. 13. Yager D, Cloutier T, Feldman H. Airway surface liquid thickness as a function of lung volume in small airways of the guinea pig. J Appl Physiol 1994; 77 (5): 2333-40
14. 14. Bastacky J, Lee C, Goerke J. Alveolar lining layer is thin and continuous: low temperature scanning electron microscopy of rat lung. J Appl Physiol 1995; 79 (5): 1615-28
15. 15. Boat TF, Cheng PW, Leigh MW. Biochemistry of mucus in airway secretion. In: Takishima T, Shimura S, editors. Airway secretion. New York: Marcel Dekker Inc., 1994: 217-82
16. 16. Montgomery R. Glycoproteins. In: Pigman W, Horton D, editors. The carbohydrates: chemistry and biochemistry. Vol. IIB: 2nd ed. New York: Academic Press, 1970: 627-709
17. 17. Thornton DJ, Carlstedt I, Howard M, et al. Respiratory mucins: identification of core proteins and glycoforms. Biochem J 1996; 316: 967-75
18. 18. Hart GJ, Bethell RC. 2,3-Didehydro-2,4-dideoxy-4-guanidino-N acetyl-D-neuraminic acid (4-guanidino-Neu5Ac2en) is a slow-binding inhibitor of sialidase from both influenza A and influenza B virus. Biochem Mol Biol Int 1995; 36: 695-703
19. 19. Corfield AP, Wember M, Schauer R, et al. The specificity of viral sialidases: the use of oligosaccharide substrates to probe enzymic characteristics and strain-specific differences. Eur J Biochem 1982; 124: 521-5
20. 20. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 1988; 61: 201-301